Kornimate/medical-research-clean huggingface dataset:
revealing engagement patterns among hepatic encephalopathy patients

Conditions: Hepatic Encephalopathy

Summary: this study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in hepatic encephalopathy clinical trials. uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors. in essence, this trial aims to deepen understanding of the factors influencing participation in hepatic encephalopathy clinical trials. elevating participation rates could expedite the development of innovative treatments for this challenging condition.


Eligibility criteria:
inclusion criteria: * signed written informed consent * aged ≥ 18 years old * no prior treatment for hepatic encephalopathy exclusion criteria: * participant is actively receiving study therapy in another * inability to provide written informed consent * women of childbearing potential without a negative pregnancy test; or women who are lactating.

Keywords: hepatic encephalopathy
evaluation of the prevalence of pelvic static disorders in women with localized breast cancer

Conditions: Breast Cancer

Summary: in this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients

breast cancer is the most common cancer in women. its incidence increases with 58,459 new cases in france in 2018, however its mortality decreases with a survival rate of 87% at 5 years. therapeutic options are surgery, radiotherapy, chemotherapy and hormone therapy. hormone therapy is one of the major treatments for hormone-sensitive tumors with a prescription made in around 70% of breast cancer cases. these different hormone therapies cause a hormonal imbalance with in particular an important anti-estrogenic action. hormonal deprivation and menopause can be responsible for the occurrence of pelvic statics disorder.\[5-9\] pelvic static disorder (pts) is a common problem for women, which can occur at any age. these disorders include urinary incontinence, stress or urgency, anal incontinence, genital prolapse. hypothesis's investigator is that hormone therapy may be responsible for pts. in this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients.

Eligibility criteria:
inclusion criteria: * women with age ≥ 50 years * menopaused * patient followed for carcinoma in situ or infiltrating the breast with or without hormone therapy * patient who was treated by surgery after june 2015, whether or not followed by radiotherapy or chemotherapy. * patient who agreed, after receiving information, to participate to the study. exclusion criteria: * metastatic breast cancer * patient with a history of pelvic static surgery * patient with a history of pelvic irradiation * patient unable or unwilling to complete the questionnaires * patient with a history of urinary incontinence treatment * patient not affiliated to the french social security system * subject under tutelage, curatorship or safeguard of justice, * patient in an emergency situation, * patient whose regular monitoring is impossible for psychological, family, social or geographical reasons, * pregnant and / or breastfeeding woman.

Keywords: localized breast cancer pelvic static disorders hormontherapy
mechanical ventilation with and without postural drainage in burn patients with ards

Conditions: Burns (Physical Finding)

Summary: inhalation injury become a more common cause of death in burn patients but alone the smoke injury has low mortality rate. it is reported that a combination of smoke injury with cutaneous burn increases the mortality rate and predispose to acute respiratory distress syndrome. this experimental study aims to report the benefits of postural drainage on the respiratory system in burn patients. this study will determine the effects of postural drainage on oxygen saturation, airway clearance in burn patients with acute respiratory distress syndrome by comparing mechanical ventilation with and without the application of postural drainage. a randomized clinical trial will be conducted in the data and will be collected from the icu of jinnah burn \& reconstructive surgery centre and shafique aziz free burn centre through consecutive sampling through technique on 50 patients which will be allocated through sealed opaque enveloped into group a and group b. pre and post treatment value of oxygenation and other variables for both group will be recorded by using apache ii. group a will be treated by postural drainage and mechanical ventilation for two consecutive days. similarly, group b will be treated by mechanical ventilation only. data will be analyzed using spss software 25. after assessing the normality of data by the shapiro-wilk test, it will be decided either parametric or non-parametric tests will be used within a group or between two groups.


Eligibility criteria:
inclusion criteria: * patients of both gender male and female are included. * patient age should be between 10-40 years * patients that are on mechanical ventilation * patients with inhalation injury * patients undergo mechanical ventilation for \>48 hours exclusion criteria: * patient with no past medical history of lung disease * subject with more than 80% of burn according to rule of nine * patients with cardiac instability such as recent myocardial infarction, unstable angina and severe hypotension and hypertension

Keywords: respiration artifical respiration postural drainage respiratory distress syndrome respiratory physiological phenomena
a phase 3 study to evaluate combination therapy with daclatasvir and sofosbuvir in the treatment of hiv and hepatitis c virus coinfection.

Conditions: Hepatitis C

Summary: a study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis c virus and hiv coinfection.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com key inclusion criteria: * patients must be able to understand and agree to/comply with the prescribed dosing regimens and procedures, report for regularly scheduled study visits, and reliably communicate with study personnel about adverse events and concomitant medications * patients chronically infected with hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6, as documented by positive hcv rna at screening * patients who are hcv treatment-naive * patients who are hcv treatment-experienced and who have had prior anti-hcv therapies discontinued or completed at least 12 weeks prior to screening * patients with hcv rna ≥10,000 iu/ml at screening * patients with hiv-1 infection key exclusion criteria: * presence of aids-defining opportunistic infections, as defined by the centers of disease control and prevention, within 12 weeks prior to study entry * patients infected with hiv-2 * liver or any other organ transplant (including hematopoietic stem cell transplants) other than cornea and hair * current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to screening * documented or suspected hepatocellular carcinoma, as evidenced by previously obtained imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this was performed * evidence of decompensated liver disease, including radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
pipeline for uncoilable or failed aneurysms

Conditions: Intracranial Aneurysm

Summary: to determine the safety and effectiveness of pipeline embolization device for the treatment of uncoilable or failed wide-necked intracranial aneurysms (ia).

patients with large or giant aneurysms of the internal carotid artery treated with ped. angiographic follow-up occurs at 3 and 5 years.

Eligibility criteria:
inclusion criteria: * age 21 to 75 years, inclusive * patient has a single target ia in the anterior or posterior circulation that: a) is located in the following regions of the internal carotid artery: i. paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments) ii. cavernous iii. petrous b) has a neck \>4 mm or no discernible neck and a size (maximum fundus diameter) \>10 mm c) has a parent vessel with diameter 2.5 - 5.0 mm distal/proximal to the target ia * subject has provided written informed consent using the institutional review board (irb)-approved consent form * subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements exclusion criteria: * more than one ia requires treatment in the next 6 months * subarachnoid hemorrhage from target ia in the past 60 days * unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days) * irreversible bleeding disorder * platelet count \< 100 x 103 cells/mm3 or known platelet dysfunction * inability to tolerate, documented evidence of adverse reaction or contraindication to study medications * stent in place at the target ia * contraindication to ct scan or mri * allergy to contrast used in angiography that cannot be medically controlled * known severe allergy to platinum or cobalt/chromium alloys * relative contraindication to angiography (e.g., serum creatinine \> 2.5 mg/dl) * woman of child-bearing potential who cannot provide a negative pregnancy test * evidence of active infection at the time of treatment * other conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis) * any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments to 180 days * extracranial stenosis greater than 50% in the carotid artery for anterior circulation aneurysms * intracranial stenosis greater than 50% in the treated vessel

Keywords: neurovascular embolization therapeutic embolization
a trial on supervised primaquine use in ethiopia

Conditions: Malaria

Summary: this is a randomized, controlled, open label trial to assess the effectiveness of unsupervised versus supervised primaquine treatment in patients with uncomplicated malaria. in co-endemic regions, the risk of p. vivax relapse following treatment for p. falciparum is high. hence patients infected with either p. vivax or p. falciparum will be included in the study. the study will be conducted in ethiopia. participants will be enrolled at health centres and provided with the recommended schizontocidal treatment plus primaquine radical cure which will be either supervised or unsupervised according to randomisation. participants will be followed up for four months and assessed at regular intervals for the presence of patent and sub-patent malaria. the outcome of the study will contribute to an improved treatment scheme for uncomplicated malaria in this area.


Eligibility criteria:
inclusion criteria: * fever (axillary temperature ≥37.5⁰c) or history of fever in preceding 48 hours * age \>5 years * weight \>5kg * written informed consent * living in the study area and willing to be followed for 4 months exclusion criteria: * general danger signs or symptoms of severe malaria (appendix 17.1 and 17.2) * anaemia, defined as hb \<8g/dl * pregnant women as determined by urine β-hcg pregnancy test * breast feeding women * known hypersensitivity to any of the drugs given * living in the same household as an individual enrolled into the study in the last 14 days
clomifene citrate versus metformin in first-line treatment of infertility in patients with polycystic ovary syndrome and a resistance to insulin

Conditions: Polycystic Ovary Syndrome; Insulin Resistance

Summary: the results of studies conducted until now does not determine what the best way to treat infertility in the first line with patients with polycystic ovary syndrome (pcos). this study objective is to determine the best treatment for such patients. the long-term consequence health of women with pcos are multiple. the woman with pcos has a risk of developing metabolic diseases, heart diseases, diabetes type ii or anovulatory infertility. the insulin resistance plays an important role in all this medical condition. clomiphene citrate (cc) remains the first line treatment to induce ovulation in women with pcos and anovulatory infertility.


Eligibility criteria:
inclusion criteria: * women aged from 18 to 35 * infertility for a period of a year or more or 6 month of irregular menstrual cycle * pcos under the rotterdam criteria * insulin resistance homa-ir \> 2.5 * normal semen analysis values * normal values of the following blood analysis: fsh, lh, estradiol, amh, tsh, prolactine, fasting glucose level, hemoglobin a1c, ast, alt, alkaline phosphatase, shbg, 17oh progesterone, dheas, androstenedione, total testosterone, ldl, hdl, total cholesterol, triglycerides, oral glucose tolerance test exclusion criteria: * tubular factor * normal ovarian reserve * prior use of cc or metformin, hypoglycemic agents, glucocorticoids, anti-androgen, weight-loss agent or oral contraceptives in the past 6 months * neoplasia * bmi \> 35 * renal, hepatic or cardiac failure * lactic, acidosis antecedent
phase 1 mecs6 + lt(r192g) vaccine study

Conditions: Diarrhea

Summary: the study will enroll approximately 60 volunteers. the vaccine is given as a drink in flavored soda water. volunteers will either receive a 3-dose vaccination with doses spaced two weeks apart or a 4-dose vaccination with doses spaced 2 days apart depending upon their availability for follow-up. once assigned to a vaccination schedule, volunteers will be randomly assigned to receive the mecs6 vaccine with or without the mlt adjuvant for all vaccine doses. neither the study investigators nor the volunteers will know which group they are assigned. volunteers will be asked to be available for clinic visits and telephone follow-ups during the study period and provide blood and stool specimens for testing.

the phase 1 section of this study is a randomized double blind trial in which a total of 60 subjects (minimum of 52 allowable) will receive on of two oral vaccine doses according to the following chart: group subset n cs6(encapsulated) lt(r192g) i a 15 0.95mg 2 micrograms ii b 15 0.95mg -- iii a 15 0.95mg 2 micrograms iv b 15 0.95mg -- \*minimum of 13 volunteers/group volunteers in group i will receive three immunizations (study days 0, 14, and 28) during the vaccine series. volunteers in group ii will receive four immunizations (study days 0, 2, 4, and 6) during the vaccine series. the two groups will be vaccinated separately for logistical purposes. blood and stool specimens will be collected at intervals to examine systemic and mucosal vaccine antigen-specific immune responses. vaccine safety will be actively evaluated during vaccination and for 4 weeks following the final vaccine dose.

Eligibility criteria:
inclusion criteria: * available for required follow-up period * women must have a negative pregnancy test * women must not to try to become pregnant while on study and for 2 months after study is completed exclusion criteria: * history of travellers' diarrhea * occupation that involves handling of e. coli or cholera bacteria, or e. coli vaccine * regular use of anti-diarrheal, anti-constipation, or antacid therapy * abnormal bowel habits * pregnant or nursing women * history of chronic gastrointestinal illness or major gastrointestinal surgery * allergies to vaccines * positive hiv, hepatitis b or hepatitis c tests * regular use of oral steroid medication * clinically significant abnormalities on physical examination

Keywords: diarrhea
assessment of surgical risk in patients with chronic liver disease using vocal penn score

Conditions: CHRONIC LIVER DISEASE

Summary: 4a. primary to assess postoperative mortality at 30 and 90 days using the vocal penn score 4b. secondary to assess potential differences in prediction accuracy between vocal-penn and meld for 30 and 90-day mortality

for each patient and surgery,we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[inr\], albumin, platelet count.) the etiology of liver disease will be classified. to ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered for each patient vocal penn score, meld score, and mayo score will be calculated using an online calculator.

Eligibility criteria:
inclusion criteria: * patients with established cirrhosis patients who had not received liver transplantation and who underwent surgery of interest were included these surgery categories will be the same as those used in the original vocal-penn derivation study and will include the open abdominal, laparoscopic abdominal, and abdominal wall. exclusion criteria: * patients with insufficient pre-operative data to compute the vocal-penn score, mayo risk score, or meld-na score will be excluded. patients undergoing liver surgeries patients who received multiple surgeries those who didn't give consent

Keywords: fluid buildup in the belly (ascites) gallstones. muscle loss.
robotic seed implantation for prostate cancer brachytherapy

Conditions: Prostate Cancer

Summary: a robotic brachytherapy device will be used to assist physicians in performing seed implantation to the prostate. euclidian is the first robotic system designed to allow automatic placement of radioactive seeds by robot and thus reduce operator dependence. the clinical study is designed to evaluate the dosimetric quality, accuracy and patient self-reported quality of life scores after robotic brachytherapy.

euclidian (endo-uro computed lattice for intratumoral delivery, implantation, ablation with nanosensing) the dose-volume histogram parameters of robotic brachytherapy will be compared to historical controls of the study institution. short-term (\<1 yr) health-related quality of life (hrqol) and changes will be assessed using fact-p and ipss self-report questionnaires.

Eligibility criteria:
inclusion criteria: * histologically confirmed, adenocarcinoma of the prostate, clinical stage t1c-t2b, nx, n0, m0. * zubrod status 0-1. * prostate tumor biopsy grading by gleason score classification is mandatory prior to registration * no prior pelvic radiation or chemotherapy for any reason; induction hormonal therapy beginning \< or = 6 months prior to registration is acceptable. * prostate volume \< or = 65 cc prior to registration, or planned use of lhrh agonist therapy for reduction of prostate volume. if lhrh agonist therapy is used to reduce prostate volume, then prostate volume must be \< or = 65 cc on the routine pre-implant volume study to be eligible for the study. * gleason score 6, or gleason score 7 if both , or = 33% of biopsy cores contain cancer and psa level is \< or = 10 ng/ml. * aua voiding symptoms score \< or = 15. * prostate specific antigen (psa) prior to study entry (and prior to any hormone treatment if given); must be \< or = 20 ng/ml. * patients must sign a study-specific consent form prior to registration (standard of care: only the standard consent form must be signed). * patient must be \> or = 40 years old. exclusion criteria: * stage t2c, t3 or t4 disease. * lymph node involvement (pathological n1) * evidence of distant metastases (m1) * gleason score 8-10. * prostate specific antigen (psa) prior to study entry \> 20 ng/ml. * aua voiding symptoms score \> 15. * radical surgery for carcinoma of the prostate. * previous hormonal therapy beginning \> 6 months prior to registration * previous or concurrent cancers other than basal or squamous cell skin cancers unless disease- free for \> or = 5 years. * major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up and/or completion of hrqol questionnaires (not a condition for ineligibility in standard of care). * prior turp * hip prosthesis

Keywords: prostate cancer euclidian endo-uro computed lattice for intratumoral delivery, implantation, ablation with nanosensing robot brachytherapy seed implantation
chest lymph node sampling in patients with advanced lung cancer to be treated with curative-intent radiation treatment

Conditions: Non-Small Cell Lung Cancer

Summary: this study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (ebus-tfna) or transesophageal ultrasound-guided fine needle aspiration (eus-fna) in patients planned to receive radical dose radiation. this study will use stereotactic ablative radiotherapy (sabr) for treatment methods. sabr is a newer radiation treatment that delivers high-dose, precise radiation to small tumors and can be delivered more accurately than with older radiation treatment methods. it is considered a standard treatment for small lung cancers, and select cancers that have spread to the brain. the purpose of this study is to compare if the lymph node sampling procedure is valuable for determining the extend of nodal disease in metastatic non-small cell lung cancer (nsclc) compared to imaging alone.


Eligibility criteria:
inclusion criteria: * patients with oligometastatic non-small cell lung cancer (nsclc), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases * radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation oncologist and/or surgeon. * age 18 years or older * good performance status (eastern cooperative oncology group \[ecog 0-1) with life-expectancy of at least 6 months as determined by enrolling physician * patient has undergone staging investigations less than 3 months prior to registration. 1. positron emission tomography (pet) / computed tomography (ct) and magnetic resonance imaging (mri) brain (ct brain with contrast if contraindication to mri) or 2. ct chest/abdomen, radionucleotide bone scan and mri of brain (ct brain with contrast if contraindication to mri) * pathologic confirmation of nsclc exclusion criteria: * contraindication to endobronchial ultrasound (ebus) / endoscopic ultrasound (eus) * unable to provide consent for ebus/eus * contraindication to chest radiotherapy * pregnant or lactating women

Keywords: oligometastatic non-small cell lung cancer stereotactic ablative radiotherapy
identification of risk allels for prostate cancer

Conditions: Prostate Cancer

Summary: identification of risk allels for prostate cancer

as above.

Eligibility criteria:
inclusion criteria: * patients with prostate cancer.